David Greenberg Sells 2,424 Shares of ICU Medical (NASDAQ:ICUI) Stock

ICU Medical, Inc. (NASDAQ:ICUI) Director David Greenberg sold 2,424 shares of the company’s stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $122.91, for a total value of $297,933.84. Following the completion of the transaction, the director directly owned 7,960 shares in the company, valued at $978,363.60. This trade represents a 23.34% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

ICU Medical Trading Down 1.0%

ICU Medical stock traded down $1.19 during mid-day trading on Wednesday, hitting $122.04. The company’s stock had a trading volume of 312,617 shares, compared to its average volume of 283,333. The company has a 50 day moving average of $126.79 and a 200-day moving average of $138.45. The stock has a market cap of $3.05 billion, a PE ratio of 65.97, a P/E/G ratio of 1.78 and a beta of 0.74. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.17 and a current ratio of 2.34. ICU Medical, Inc. has a one year low of $107.00 and a one year high of $160.29.

ICU Medical (NASDAQ:ICUI) last announced its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $1.97 EPS for the quarter, beating the consensus estimate of $1.78 by $0.19. The company had revenue of $525.77 million for the quarter, compared to the consensus estimate of $520.65 million. ICU Medical had a return on equity of 7.50% and a net margin of 2.15%.ICU Medical’s quarterly revenue was down 12.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.72 EPS. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. On average, research analysts anticipate that ICU Medical, Inc. will post 6.31 EPS for the current year.

Analyst Upgrades and Downgrades

ICUI has been the topic of several research analyst reports. KeyCorp cut their price objective on ICU Medical from $180.00 to $164.00 and set an “overweight” rating on the stock in a research report on Monday, April 27th. Piper Sandler lowered their target price on ICU Medical from $178.00 to $163.00 and set an “overweight” rating for the company in a report on Friday, April 17th. Jefferies Financial Group upgraded ICU Medical to a “strong-buy” rating in a report on Thursday, May 7th. Weiss Ratings upgraded ICU Medical from a “sell (d)” rating to a “sell (d+)” rating in a report on Monday. Finally, Wall Street Zen upgraded ICU Medical from a “hold” rating to a “buy” rating in a report on Saturday. Two research analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $169.00.

Institutional Investors Weigh In On ICU Medical

Hedge funds have recently made changes to their positions in the stock. Hilton Head Capital Partners LLC purchased a new stake in shares of ICU Medical during the 4th quarter worth $32,000. Covestor Ltd lifted its stake in shares of ICU Medical by 70.7% during the 3rd quarter. Covestor Ltd now owns 570 shares of the medical instruments supplier’s stock worth $68,000 after purchasing an additional 236 shares during the last quarter. Strs Ohio lifted its stake in shares of ICU Medical by 60.0% during the 4th quarter. Strs Ohio now owns 800 shares of the medical instruments supplier’s stock worth $114,000 after purchasing an additional 300 shares during the last quarter. Rockefeller Capital Management L.P. lifted its stake in shares of ICU Medical by 21.6% during the 4th quarter. Rockefeller Capital Management L.P. now owns 823 shares of the medical instruments supplier’s stock worth $117,000 after purchasing an additional 146 shares during the last quarter. Finally, Kemnay Advisory Services Inc. purchased a new stake in shares of ICU Medical during the 4th quarter worth $120,000. 96.10% of the stock is currently owned by hedge funds and other institutional investors.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.